Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Last trade$304.70
Day change-$5.57 (-1.80%)
Day range$302.90 – $320.57
Volume525,313
Market cap$8.67B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.67B
Price / earnings
—
Price / book
6.89×
Price / sales
—
EV / sales
—
EV / EBITDA
-20.44×
Profitability
Earnings per share
-$12.86
Return on assets
-27.39%
Return on equity
-28.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.53×
Quick ratio
14.53×
Cash ratio
6.89×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$323.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRAX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$7.46M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$7.46M
Selling, general and administrative
$42.71M
$27.49M
$27.87M
$19.54M
$12.56M
$13.06M
$13.92M
$15.13M
Research and development
$64.21M
$69.42M
$77.99M
$77.51M
$65.8M
$63.01M
$60.81M
$56.29M
Total operating expenses
$106.91M
$96.9M
$105.86M
$97.04M
$78.36M
$76.07M
$74.73M
$71.42M
Operating income
-$106.91M
-$96.9M
-$105.86M
-$97.04M
-$78.36M
-$76.07M
-$74.73M
-$63.96M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$94.23M
-$83.72M
-$92.56M
-$88.91M
-$73.93M
-$71.13M
-$69.3M
-$58.68M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$94.23M
-$83.72M
-$92.56M
-$88.91M
-$73.93M
-$71.13M
-$69.3M
-$58.68M
Net income attributable to common shareholders
-$94.23M
-$83.72M
-$92.56M
-$88.91M
-$73.93M
-$71.13M
-$69.3M
-$58.68M
EBITDA
-$106.88M
-$96.87M
-$105.82M
-$97.02M
-$78.34M
-$76.02M
-$74.68M
-$63.91M
Basic earnings per share
-$3.23
-$2.87
-$3.20
-$3.49
-$3.36
-$3.31
-$3.29
-$2.93
Diluted earnings per share
-$3.23
-$2.87
-$3.20
-$3.49
-$3.36
-$3.31
-$3.29
-$2.93
Recent news
Company coverage with links to the original publishers.
Praxis Precision Medicines (NASDAQ: PRAX) shares surged 7.15% on Tuesday following FDA acceptance of its New Drug Application for ulixacaltamide, a treatment for essential tremor, with an FDA decision target date of January 29, 2027. The company also reported positive Phase 3 trial results and significant seizure reduction data from its elsunersen program. The stock is trading near its 52-week high with strong technical momentum and a Buy rating from analysts with a $588.60 average price target.
Praxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients showed improvements in sleep, motor function, and attention, with no serious adverse events reported.
Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.
Deerfield Management Company increased its stake in Praxis Precision Medicines by 62,500 shares, bringing its total position to $266.25 million. PRAX stock has surged 685% over the past year, significantly outperforming the S&P 500. The biotech company recently submitted FDA applications for two drug candidates and has four leading programs that could represent over $20 billion in potential revenue if successfully commercialized. With $926 million in cash and a recent $621 million offering, Praxis is well-positioned financially through 2028.
Praxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceeding $20 billion if approved, the company is positioned for significant growth, though regulatory approval remains a key risk.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.